News | May 02, 2026
FDA grants breakthrough status to Laguna's mRNA blood test for schizophrenia diagnosis
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
The online platform is designed to go beyond clinical treatment, offering practical tools, lived-experience insights, and peer-informed support intended to reduce isolation and improve day-to-day coping
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
Alto met its enrollment goal with 83 patients across 13 US clinical sites
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Subscribe To Our Newsletter & Stay Updated
